These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25848203)

  • 1. Current perspectives on ranibizumab.
    Dedania VS; Bakri SJ
    Clin Ophthalmol; 2015; 9():533-42. PubMed ID: 25848203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
    Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA
    Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
    Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC; Brown DM; Payne JF; Wykoff CC
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.
    Buyru Özkurt Y; Akkaya S; Aksoy S; Şimşek MH
    Eur J Ophthalmol; 2018 Nov; 28(6):690-696. PubMed ID: 29696993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
    Mukkamala L; Bhagat N; Zarbin MA
    Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.
    Chatziralli I; Theodossiadis G; Chatzirallis A; Parikakis E; Mitropoulos P; Theodossiadis P
    Retina; 2018 Mar; 38(3):559-568. PubMed ID: 28248827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion.
    Unsal E; Eltutar K; Sultan P; Gungel H
    Pak J Med Sci; 2015; 31(3):510-5. PubMed ID: 26150834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab and retinal vein occlusion. Too many outstanding questions.
    Prescrire Int; 2012 Sep; 21(130):207. PubMed ID: 23016250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
    Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S
    J Fr Ophtalmol; 2016 Dec; 39(10):816-821. PubMed ID: 27865689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Grid Laser Photocoagulation and a Single Intravitreal Ranibizumab as an Efficient and Cost-Effective Treatment Option for Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Cao W; Cui H; Biskup E
    Rejuvenation Res; 2019 Aug; 22(4):335-341. PubMed ID: 30444191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept: an update on recent milestones achieved.
    Palejwala NV; Lauer AK
    Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.